SufA of the opportunistic pathogen finegoldia magna modulates actions of the antibacterial chemokine MIG/CXCL9, promoting bacterial survival during epithelial inflammation.
The anaerobic bacterium Finegoldia magna is part of the human commensal microbiota, but is also an important opportunistic pathogen. This bacterium expresses a subtilisin-like serine proteinase, SufA, which partially degrade the antibacterial chemokine MIG/CXCL9. Here, we show that MIG/CXCL9 is produced by human keratinocytes in response to inflammatory stimuli. In contrast to the virulent human pathogen Streptococcus pyogenes, the presence of F. magna had no enhancing effect on the MIG/CXCL9 expression by keratinocytes, suggesting poor detection of the latter by pathogen-recognition receptors. When MIG/CXCL9 was exposed to SufA-expressing F. magna, the molecule was processed into several smaller fragments. Analysis by mass spectrometry showed that SufA cleaves MIG/CXCL9 at several sites in the COOH-terminal region of the molecule. At equimolar concentrations, SufA-generated MIG/CXCL9 fragments were not bactericidal against F. magna, but retained their ability to kill S. pyogenes. Moreover, the SufA-generated MIG/CXCL9 fragments were capable of activating the angiostasis-mediating CXCR3 receptor, which is expressed on endothelial cells, in an order of magnitude similar to that of intact MIG/CXCL9. F. magna expresses a surface protein called FAF that is released from the bacterial surface by SufA. Soluble FAF was found to bind and inactivate the antibacterial activity of MIG/CXCL9, thereby further potentially promoting the survival of F. magna. The findings suggest that SufA modulation of the inflammatory response could be a mechanism playing an important role in creating an ecologic niche for F. magna, decreasing antibacterial activity and suppressing angiogenesis, thus providing advantage in survival for this anaerobic opportunist compared with competing pathogens during inflammation.
Karlsson
Christofer
C
Division of Infection, Department of Clinical Sciences Lund, Lund University, SE-22184 Lund, Sweden.
Eliasson
Mette
M
Olin
Anders I
AI
Mörgelin
Matthias
M
Karlsson
Anna
A
Malmsten
Martin
M
Egesten
Arne
A
Frick
Inga-Maria
IM
D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism* / Q000494:pharmacology; D001426:Bacterial Proteins / Q000378:metabolism*; D002460:Cell Line; D054370:Chemokine CXCL9 / Q000378:metabolism* / Q000494:pharmacology; D016908:Gram-Positive Bacterial Infections / Q000378:metabolism; D016937:Gram-Positive Endospore-Forming Rods / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D015603:Keratinocytes / Q000378:metabolism*; D051379:Mice; D018919:Neovascularization, Physiologic / Q000187:drug effects; D054367:Receptors, CXCR3 / Q000819:agonists / Q000378:metabolism; D012697:Serine Endopeptidases / Q000378:metabolism*; D013297:Streptococcus pyogenes / Q000378:metabolism
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; C080810:CXCL9 protein, human; C515187:CXCR3 protein, human; D054370:Chemokine CXCL9; D054367:Receptors, CXCR3; D012697:Serine Endopeptidases